There’s a biotech company going public right now
As you might have heard, the S&P 500 is down roughly 30% over the past month. The Dow Jones Industrial Average has fallen about as much in the same period. CNBC has even resurrected its most beloved chyron.
To the people who run a biotech company called Keros Therapeutics, this is the time to go public.
As STAT’s Kate Sheridan reports, the company just raised $56 million in a private funding round just this month but apparently needs even more cash to keep things running. Keros, based in Massachusetts, is developing drugs that manipulate a receptor called TGF-beta, a popular target for scientists looking for a way to make immuno-oncology drugs more effective.
Read more.
To the people who run a biotech company called Keros Therapeutics, this is the time to go public.
As STAT’s Kate Sheridan reports, the company just raised $56 million in a private funding round just this month but apparently needs even more cash to keep things running. Keros, based in Massachusetts, is developing drugs that manipulate a receptor called TGF-beta, a popular target for scientists looking for a way to make immuno-oncology drugs more effective.
Read more.
.png)
No hay comentarios:
Publicar un comentario